Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Earnings Data
Report Date
May 20, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.34Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted several strong positives: a transformative one-time gain from the priority review voucher that produced a substantial net income swing and strengthened cash; regulatory and reimbursement progress (J-code and broad payer coverage); growing patient identification (50 to +100); and an on-track manufacturing capacity expansion to ~10 patients/month. However, meaningful operational risks and near-term commercialization challenges remain: an earlier sterility-related batch failure and launch delay, slow initial patient throughput (only two treated to date), a lengthy 4–5 month timeline from consult to treatment, and sharply higher SG&A as the company transitions to commercial operations. While early commercial traction is improving and the company has sufficient liquidity, execution of QTC onboarding and consistent patient cadence are critical to meet profitability and scale expectations.Company Guidance
Major Non-Operating Gain from Priority Review Voucher Sale
Recorded a $1,524,000,000 gain on sale of a rare pediatric disease priority review voucher (sale completed June 2025), materially improving 2025 profitability and liquidity.
Profitability and EPS Swing
Net income of $71,200,000 for the year ended 12/31/2025 (basic EPS $1.034; diluted $1.10) versus a net loss of $63,700,000 in 2024 — a year-over-year improvement of $134,900,000.
Strong Cash Position
Cash, cash equivalents, and short-term investments totaled $191,400,000 as of 12/31/2025, providing runway to support commercialization and operational buildout.
Regulatory and Reimbursement Milestones
ZivaSkin approved April 2025; CMS established a permanent HCPCS J-code effective 01/01/2026; major commercial payers (UnitedHealthcare, Cigna, Aetna, Anthem and most Blue Cross Blue Shield plans) have published coverage policies covering roughly 80% of commercially covered lives; baseline Medicaid coverage across all 50 states.
Commercial Launch Momentum and Growing Patient Identification
Launch resumed after sterility optimization with first commercial treatment in December 2025. Identified eligible patient pool grew from nearly 50 to more than 100 following deployment of field team and outreach to community physicians.
Qualified Treatment Centers and Onboarding Plan
Four QTCs activated (two already treating — Lurie Children’s and Lucile Packard); two additional QTCs (Children's Hospital of Colorado and UTMB Galveston) beginning to schedule patients; company is working to onboard five more centers with a target of at least seven QTCs active by end of 2026 to expand geographic access.
Manufacturing Capacity and Sterility Resolution
CTO reports confidence in resolution of the prior sterility test issue. Current manufacturing cadence ~6 patients/month with plan to expand to ~10 patients/month by H2 2026, aligning capacity with expected site onboarding.
Revenue Mix and Early Product Revenue
Total revenue for 2025 of $5.8M, comprised of $3.4M in license and other revenue (driven by a $3.0M clinical milestone under a sublicense) and $2.4M in net product revenue reflecting initial commercial patient treatments (payment for December treatment received in 2026).
ABEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 17, 2026 | $4.95 | $4.76 | -3.84% |
Nov 12, 2025 | $4.17 | $4.94 | +18.47% |
Aug 14, 2025 | $6.56 | $7.23 | +10.21% |
May 15, 2025 | $5.39 | $5.79 | +7.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Abeona Therapeutics (ABEO) report earnings?
Abeona Therapeutics (ABEO) is schdueled to report earning on May 20, 2026, TBA (Confirmed).
What is Abeona Therapeutics (ABEO) earnings time?
Abeona Therapeutics (ABEO) earnings time is at May 20, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABEO EPS forecast?
ABEO EPS forecast for the fiscal quarter 2026 (Q1) is -0.34.